NCT06826196View on ClinicalTrials.gov

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 24, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

June 30, 2026

Conditions
Alopecia Areata (AA)
Interventions
DRUG

ALD-102

Treatment every 4 weeks for total of 8-week treatment period.

DRUG

Placebo

Treatment every 4 weeks for 8-week treatment period

Trial Locations (5)

47906

RECRUITING

Options Research Group, West Lafayette

99202

RECRUITING

Dermatology Specialists of Spokane, Spokane

L6J 7W5

RECRUITING

The Centre for Clinical Trials, Oakville

H2X 2V1

RECRUITING

Innovaderm, Montreal

QC G1W 4R4

RECRUITING

Centre de Recherche Saint-Louis, Québec

Sponsors
All Listed Sponsors
lead

Aldena Therapeutics

INDUSTRY

NCT06826196 - A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata | Biotech Hunter | Biotech Hunter